RxDoctor Payments Data

Rahmat Gul

Family · Troy, NYNPI 1699443911

Payments from drug & device makers

$872in general payments, 2019–2025

Across 46 payments — averaging $18.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$171
  • GSK$110
  • Lilly USA, LLC$107
  • Bayer$69
  • AstraZeneca$63
  • Otsuka America Pharmaceutical, Inc.$59
  • plus $294 from 10 others

What the payments were for

  • Food & beverage$872100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$872 in reported general payments places this provider in the 70th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$22,438
Medicare patients
111
Services billed
414

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide44$61,190
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$32,146
EliquisApixaban35$31,403
FarxigaDapagliflozin Propanediol38$31,245
JanuviaSitagliptin Phosphate19$20,826
JardianceEmpagliflozin16$17,603
MounjaroTirzepatide14$16,483
Combivent RespimatIpratropium/Albuterol Sulfate11$13,611
MyrbetriqMirabegron35$12,309
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$7,019
Divalproex Sodium50$3,922
Lantus SolostarInsulin Glargine,hum.Rec.Anlog23$3,782
Albuterol Sulfate HfaAlbuterol Sulfate67$2,564
Potassium Chloride49$2,073
Gabapentin105$1,916

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$171$61,19044 claims
AstraZenecaFarxiga, Breztri Aerosphere$63$38,26449 claims
GSKTrelegy Ellipta$110$32,14622 claims
Lilly USA, LLCMounjaro$107$16,48314 claims
Astellas Pharma US IncMyrbetriq$18$12,30935 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,883 family providers in New York.

Other family in Troy

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →